Cytotoxic T Lymphocyte Protein 4 Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4 Pipeline Review, H2 2018
Summary
Cytotoxic T Lymphocyte Protein 4 Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4 CTLA4 also known as CD152 is a protein receptor found on the surface of T cells. It functions as an immune checkpoint and down regulates the immune system. The affinity of CTLA4 for its natural B7 family ligands, CD80 and CD86, is considerably stronger than the affinity of their cognate stimulatory coreceptor CD28. Inhibition of receptor acts as a major negative regulator of Tcell responses.
Cytotoxic T Lymphocyte Protein 4 Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4 pipeline Target constitutes close to 52 molecules. Out of which approximately 51 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in PreRegistration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 3, 5, 10, 1, 23 and 8 respectively.
Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology and Infectious Disease which include indications Solid Tumor, NonSmall Cell Lung Cancer, Gastric Cancer, Breast Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hepatocellular Carcinoma, Melanoma, Metastatic Melanoma, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Adenocarcinoma Of The Gastroesophageal Junction, Bladder Cancer, Cervical Cancer, Colon Cancer, Colorectal Cancer, Gastroesophageal GE Junction Carcinomas, Muscle Invasive Bladder Cancer MIBC, Nasopharyngeal Cancer, Renal Cell Carcinoma, SmallCell Lung Cancer, Adenoid Cystic Carcinoma ACC, Anaplastic Thyroid Cancer, Diffuse Large BCell Lymphoma, Endometrial Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Germ Cell Tumors, Hematological Tumor, Hodgkin Lymphoma BCell Hodgkin Lymphoma, Malignant Pleural Mesothelioma, Merkel Cell Carcinoma, Metastatic Colorectal Cancer, Metastatic Hormone Refractory Castration Resistant, AndrogenIndependent Prostate Cancer, Metastatic Transitional Urothelial Tract Cancer, Neuroendocrine Gastroenteropancreatic Tumors GEPNET, NonHodgkin Lymphoma, Ovarian Cancer, Peritoneal Cancer, Vaginal Cancer, Vulvar Cancer, Adrenal Gland Cancer, Adrenocortical Carcinoma Adrenal Cortex Cancer, Advanced Malignancy, Anal Cancer, Basal Cell Carcinoma Basal Cell Epithelioma, Bile Duct Cancer Cholangiocarcinoma, Chronic Myelocytic Leukemia CML, Chronic Myeloid Leukemia, Dedifferentiated Liposarcoma, Dysgerminoma, Ependymoma, EpsteinBarr Virus HHV4 Infections, Esophageal Cancer, Ewing Sarcoma, Gallbladder Cancer, Germinomatous Seminomatous Germ Cell Tumors, Head And Neck Cancer, HighGrade Glioma, Hormone Refractory Castration Resistant, AndrogenIndependent Prostate Cancer, Human Immunodeficiency Virus HIV Infections AIDS, Kaposi Sarcoma, Lymphoma, Malignant Fibrous Histiocytoma, Malignant Mesothelioma, Medullary Thyroid Cancer, Medulloblastoma, Meningioma, Metastatic Breast Cancer, Metastatic Cancer, Metastatic Liver Cancer, Metastatic Lung Cancer, Metastatic Pancreatic Cancer, Metastatic Prostate Cancer, Metastatic Renal Cell Carcinoma, Metastatic Uveal Melanoma, Multiple Myeloma Kahler Disease, Neuroblastoma, NonSmall Cell Lung Carcinoma, Nongerminomatous Nonseminomatous Germ Cell Tumors, Oropharyngeal Cancer, Osteosarcoma, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Papillary Renal Cell Carcinoma, Pediatric Diffuse Intrinsic Pontine Glioma, Penile Cancer, Primitive Neuroectodermal Tumor PNET, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Rhabdomyosarcoma, Salivary Gland Cancer, Soft Tissue Sarcoma, Squamous Cell Carcinoma, Squamous NonSmall Cell Lung Cancer, Transitional Cell Cancer Urothelial Cell Cancer, Transitional Cell Carcinoma Urothelial Cell Carcinoma, Ureter Cancer, Urethral Cancer and Urinary Tract Cancer.
The latest report Cytotoxic T Lymphocyte Protein 4 Pipeline Review, H2 2018, outlays comprehensive information on the Cytotoxic T Lymphocyte Protein 4 Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type. It also reviews key players involved in Cytotoxic T Lymphocyte Protein 4 Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4 targeted therapeutics development with respective active and dormant or discontinued projects.
The report is
IntroductionGlobal Markets Direct Report CoverageGlobal Markets Direct's, Cytotoxic T Lymphocyte Protein 4 Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4 H2 2018, provides in depth analysis on Cytotoxic T Lymphocyte Protein 4 Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4 targeted pipeline therapeutics. The report provides comprehensive information on the Cytotoxic T Lymphocyte Protein 4 Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cytotoxic T Lymphocyte Protein 4 Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4 targeted therapeutics development with respective active and dormant or discontinued projects.Cytotoxic T Lymphocyte Protein 4 Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4 pipeline Target constitutes close to 52 molecules. Out of which approximately 51 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in PreRegistration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 3, 5, 10, 1, 23 and 8 respectively.
Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology and Infectious Disease which include indications Solid Tumor, NonSmall Cell Lung Cancer, Gastric Cancer, Breast Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hepatocellular Carcinoma, Melanoma, Metastatic Melanoma, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Adenocarcinoma Of The Gastroesophageal Junction, Bladder Cancer, Cervical Cancer, Colon Cancer, Colorectal Cancer, Gastroesophageal GE Junction Carcinomas, Muscle Invasive Bladder Cancer MIBC, Nasopharyngeal Cancer, Renal Cell Carcinoma, SmallCell Lung Cancer, Adenoid Cystic Carcinoma ACC, Anaplastic Thyroid Cancer, Diffuse Large BCell Lymphoma, Endometrial Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Germ Cell Tumors, Hematological Tumor, Hodgkin Lymphoma BCell Hodgkin Lymphoma, Malignant Pleural Mesothelioma, Merkel Cell Carcinoma, Metastatic Colorectal Cancer, Metastatic Hormone Refractory Castration Resistant, AndrogenIndependent Prostate Cancer, Metastatic Transitional Urothelial Tract Cancer, Neuroendocrine Gastroenteropancreatic Tumors GEPNET, NonHodgkin Lymphoma, Ovarian Cancer, Peritoneal Cancer, Vaginal Cancer, Vulvar Cancer, Adrenal Gland Cancer, Adrenocortical Carcinoma Adrenal Cortex Cancer, Advanced Malignancy, Anal Cancer, Basal Cell Carcinoma Basal Cell Epithelioma, Bile Duct Cancer Cholangiocarcinoma, Chronic Myelocytic Leukemia CML, Chronic Myeloid Leukemia, Dedifferentiated Liposarcoma, Dysgerminoma, Ependymoma, EpsteinBarr Virus HHV4 Infections, Esophageal Cancer, Ewing Sarcoma, Gallbladder Cancer, Germinomatous Seminomatous Germ Cell Tumors, Head And Neck Cancer, HighGrade Glioma, Hormone Refractory Castration Resistant, AndrogenIndependent Prostate Cancer, Human Immunodeficiency Virus HIV Infections AIDS, Kaposi Sarcoma, Lymphoma, Malignant Fibrous Histiocytoma, Malignant Mesothelioma, Medullary Thyroid Cancer, Medulloblastoma, Meningioma, Metastatic Breast Cancer, Metastatic Cancer, Metastatic Liver Cancer, Metastatic Lung Cancer, Metastatic Pancreatic Cancer, Metastatic Prostate Cancer, Metastatic Renal Cell Carcinoma, Metastatic Uveal Melanoma, Multiple Myeloma Kahler Disease, Neuroblastoma, NonSmall Cell Lung Carcinoma, Nongerminomatous Nonseminomatous Germ Cell Tumors, Oropharyngeal Cancer, Osteosarcoma, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Papillary Renal Cell Carcinoma, Pediatric Diffuse Intrinsic Pontine Glioma, Penile Cancer, Primitive Neuroectodermal Tumor PNET, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Rhabdomyosarcoma, Salivary Gland Cancer, Soft Tissue Sarcoma, Squamous Cell Carcinoma, Squamous NonSmall Cell Lung Cancer, Transitional Cell Cancer Urothelial Cell Cancer, Transitional Cell Carcinoma Urothelial Cell Carcinoma, Ureter Cancer, Urethral Cancer and Urinary Tract Cancer.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
The report provides a snapshot of the global therapeutic landscape for Cytotoxic T Lymphocyte Protein 4 Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4
The report reviews Cytotoxic T Lymphocyte Protein 4 Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in Cytotoxic T Lymphocyte Protein 4 Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4 targeted therapeutics and enlists all their major and minor projects
The report assesses Cytotoxic T Lymphocyte Protein 4 Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Cytotoxic T Lymphocyte Protein 4 Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4 targeted therapeutics
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Cytotoxic T Lymphocyte Protein 4 Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Cytotoxic T Lymphocyte Protein 4 Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4 development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope